Disrupted in Schizophrenia 1 (DISC1) (DISC1)

Disrupted in Schizophrenia 1 (DISC1) is a multi-functional scaffold protein that plays a pivotal role in orchestrating signaling pathways essential for neurodevelopment, including neuronal proliferation, migration, and synaptogenesis [1.4.2, 1.5.2]. It acts as a central hub in the DISC1 interactome, coordinating the activity of various binding partners such as GSK3β, PDE4, and NDEL1 to maintain synaptic plasticity and intracellular transport [1.1.1, 1.3.2]. Misfolding and subsequent aggregation of DISC1 have been identified as a pathological hallmark in a subset of patients with major psychiatric disorders, including schizophrenia and bipolar disorder [1.2.1, 1.2.3]. These aggregates are thought to cause a loss of normal scaffolding function and a potential toxic gain-of-function, disrupting critical cellular processes like mitochondrial transport [1.3.3, 1.5.4]. Therapeutic strategies targeting misfolded DISC1 focus on stabilizing its native conformation, inhibiting the formation of toxic oligomers, or utilizing selective monoclonal antibodies to clear aggregated species [1.2.4, 1.3.1]. While traditional antipsychotics and mood stabilizers like clozapine and lithium can modulate DISC1-related pathways, novel precision interventions are being developed to directly address the underlying proteinopathy [1.3.2, 1.3.5]. Research into DISC1 aggregation models has also highlighted its role in dopaminergic dysregulation, suggesting that targeting the misfolded protein could recalibrate disrupted neural networks and improve social and cognitive outcomes in psychiatric patients [1.3.1, 1.3.5].

Other names

Disrupted in schizophrenia 1C1orf136SCZD1DISC-1

Stabilization of native protein conformation, inhibition of protein aggregation and oligomerization, clearance of misfolded species via proteostasis mechanisms (e.g., chaperone-mediated autophagy), and modulation of the DISC1 interactome to restore downstream signaling.